Premium
Type‐I interferons suppress microglial production of the lymphoid chemokine, CXCL13
Author(s) -
Esen Nilufer,
RaineyBarger Emily K.,
Huber Amanda K.,
Blakely Pennelope K.,
Irani David N.
Publication year - 2014
Publication title -
glia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.954
H-Index - 164
eISSN - 1098-1136
pISSN - 0894-1491
DOI - 10.1002/glia.22692
Subject(s) - cxcl13 , biology , microglia , chemokine , neuroinflammation , immunology , interferon , chemokine receptor , ccl21 , microbiology and biotechnology , inflammation
Lymphoid chemokines are crucial for the development and maintenance of lymphoid organs, but their ectopic expression in non‐lymphoid tissues is implicated in both local response to infection and chronic organ‐specific autoimmunity. Production of one such chemokine, C‐X‐C motif ligand 13 (CXCL13), within the central nervous system (CNS) has been linked to the pathogenesis of multiple sclerosis (MS), although little is known about factors controlling its expression in different neural cell types and across a range of disease states. We provoked acute neuroinflammation in experimental animals without causing any associated demyelination using neuroadapted Sindbis virus (NSV) to better understand the sources and regulators of this chemokine in the CNS. We found that mice genetically deficient in the transcription factor, interferon (IFN) regulatory factor‐7 (IRF7), made significantly higher CXCL13 protein levels in the CNS compared with wild‐type (WT) controls. Microglia proved to be the main producer of CXCL13 in the brain during infection of both WT and IRF7 −/− mice, and primary microglia cultured in vitro generated CXCL13 following stimulation with either virus particles or synthetic Toll‐like receptor (TLR) ligands. Microglia cultured from IRF7 −/− mice selectively overproduced CXCL13, and manipulation of extracellular type‐I IFN levels demonstrated the existence of a negative feedback loop whereby type‐I IFN receptor signaling specifically suppressed microglial CXCL13 release. Since IFN‐β is used to treat patients with relapsing‐remitting MS and yet acts through unknown mechanisms, we speculate that suppressed lymphoid chemokine production by microglia could contribute to its therapeutic effects. GLIA 2014;62:1452–1462